These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 15485310)

  • 21. Clinical trial simulation of a 200-microg fixed dose of darbepoetin alfa in chemotherapy-induced anemia.
    Jumbe N; Yao B; Rovetti R; Rossi G; Heatherington AC
    Oncology (Williston Park); 2002 Oct; 16(10 Suppl 11):37-44. PubMed ID: 12435172
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic evaluation of darbepoetin alfa for the treatment of pediatric patients with chemotherapy-induced anemia.
    Blumer J; Berg S; Adamson PC; Loew T; Rossi G; Hastings C
    Pediatr Blood Cancer; 2007 Oct; 49(5):687-93. PubMed ID: 17120240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Darbepoetin alfa: a review of its use in the treatment of anaemia in patients with cancer receiving chemotherapy.
    Siddiqui MA; Keating GM
    Drugs; 2006; 66(7):997-1012. PubMed ID: 16740021
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of darbepoetin alfa for the treatment of chemotherapy-induced anaemia.
    Vansteenkiste J; Wauters I
    Expert Opin Pharmacother; 2005 Mar; 6(3):429-40. PubMed ID: 15794734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effectiveness of darbepoetin alfa administered every 3 weeks on hematologic outcomes and quality of life in older patients with chemotherapy-induced anemia.
    Boccia R; Lillie T; Tomita D; Balducci L
    Oncologist; 2007 May; 12(5):584-93. PubMed ID: 17522247
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
    Hertel J; Locay H; Scarlata D; Jackson L; Prathikanti R; Audhya P
    Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of latent growth curve models for assessing the effects of darbepoetin alfa on hemoglobin and fatigue.
    Stull DE; Vernon MK; Legg JC; Viswanathan HN; Fairclough D; Revicki DA
    Contemp Clin Trials; 2010 Mar; 31(2):172-9. PubMed ID: 20060499
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial.
    ; Glaspy J; Vadhan-Raj S; Patel R; Bosserman L; Hu E; Lloyd RE; Boccia RV; Tomita D; Rossi G
    J Clin Oncol; 2006 May; 24(15):2290-7. PubMed ID: 16710026
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Darbepoetin alpha coming of age.
    Pedrazzoli P; Cinieri S; Lorusso V; Gamucci T; Secondino S; Silvestris N
    Anticancer Res; 2007; 27(6C):4419-24. PubMed ID: 18214054
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients.
    Nissenson AR; Swan SK; Lindberg JS; Soroka SD; Beatey R; Wang C; Picarello N; McDermott-Vitak A; Maroni BJ
    Am J Kidney Dis; 2002 Jul; 40(1):110-8. PubMed ID: 12087568
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial.
    Charu V; Belani CP; Gill AN; Bhatt M; Tomita D; Rossi G; Ben-Jacob A
    Oncologist; 2007 Jun; 12(6):727-37. PubMed ID: 17602062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
    Skali H; Lin J; Pfeffer MA; Chen CY; Cooper ME; McMurray JJ; Nissenson AR; Remuzzi G; Rossert J; Parfrey PS; Scott-Douglas NW; Singh AK; Toto R; Uno H; Ivanovich P
    Am J Kidney Dis; 2013 Feb; 61(2):238-46. PubMed ID: 23159232
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluating erythropoietic agents for the treatment of anaemia in the oncology setting.
    Gascón P
    Eur J Cancer; 2005 Nov; 41(17):2601-12. PubMed ID: 16230006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regarding "randomized comparison of epoetin alfa and darbepoetin alfa in anemic patients with cancer receiving chemotherapy".
    Nowrousian MR
    Oncologist; 2006 May; 11(5):535-6; author reply 536-7. PubMed ID: 16720859
    [No Abstract]   [Full Text] [Related]  

  • 35. Epoetin alfa and darbepoetin alfa go head to head.
    Steensma DP; Loprinzi CL
    J Clin Oncol; 2006 May; 24(15):2233-6. PubMed ID: 16710021
    [No Abstract]   [Full Text] [Related]  

  • 36. Treating anemia of cancer with every-4-week darbepoetin alfa: final efficacy and safety results from a phase II, randomized, double-blind, placebo-controlled study.
    Gordon D; Nichols G; Ben-Jacob A; Tomita D; Lillie T; Miller C
    Oncologist; 2008 Jun; 13(6):715-24. PubMed ID: 18586927
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia.
    Auerbach M; Silberstein PT; Webb RT; Averyanova S; Ciuleanu TE; Shao J; Bridges K
    Am J Hematol; 2010 Sep; 85(9):655-63. PubMed ID: 20661916
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia.
    Hernandez E; Ganly P; Charu V; Dibenedetto J; Tomita D; Lillie T; Taylor K;
    Curr Med Res Opin; 2009 Sep; 25(9):2109-20. PubMed ID: 19601709
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of cancer-related anemia with erythropoietic agents: doubts, certainties, and concerns.
    Stasi R; Amadori S; Littlewood TJ; Terzoli E; Newland AC; Provan D
    Oncologist; 2005 Aug; 10(7):539-54. PubMed ID: 16079321
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment of renal anemia with darbepoetin alfa: results of an Austrian multicenter study].
    Hörl WH; Holzer H; Mayer GJ;
    Wien Klin Wochenschr; 2002 Dec; 114(23-24):967-71. PubMed ID: 12635463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.